BLRX Earnings & Financial Statements
BioLineRx Ltd.
$2.05
-$0.03(-1.20%)
41
Overall
--
Value
40
Tech
42
Quality
Market Cap
$10.33M
Volume
28.75K
52W Range
$2.15 - $4.15
Target Price
$22.00
BLRX earnings and financial statements: BioLineRx Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BLRX Annual Financial Statements
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | $28.94M | $4.80M | - | - | -$1.63M |
| Cost of revenue | $9.26M | $3.69M | - | - | - |
| Operating income | -$963.0K | -$32.17M | -$31.32M | -$25.78M | -$24.56M |
| EBITDA | -$102.0K | -$36.81M | -$22.51M | -$25.37M | -$27.62M |
| Net income | -$9.22M | -$38.98M | -$24.95M | -$27.05M | -$30.02M |
| EPS (diluted) | $-0.01 | $-0.06 | $-0.45 | $-24.00 | $-72.00 |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $38.91M | $63.92M | $76.38M | $68.40M | $33.20M |
| Total liabilities | $25.45M | $50.70M | $25.54M | $34.37M | $32.39M |
| Shareholders’ equity | $13.46M | $13.22M | $23.73M | $47.02M | $12.16M |
| Cash and equivalents | $10.44M | $4.25M | $40.49M | $44.15M | $5.76M |
| Long-term debt | $10.04M | $7.92M | $1.73M | $1.73M | $1.66M |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$43.87M | -$22.61M | -$26.24M | -$101.57M | -$56.71M |
| Capital expenditure | - | - | -$316.0K | -$97.0K | - |
| Free cash flow | -$43.93M | -$22.91M | -$26.56M | -$101.67M | -$56.71M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $2.05 | -1.2% | 28.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |